Professional
Added to YB: 2024-09-05
Pitch date: 2024-07-11
EXAS [bullish]
Exact Sciences Corporation
+126.91%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Market Cap
$19.7B
Pitch Price
$45.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
187.48
P/E
-93.68
EV/Sales
6.55
Sector
Biotechnology
Category
growth
Show full summary:
Columbia Acorn Fund Portfolio Holding: Exact Sciences Corporation
EXAS: Leading cancer screening provider w/ Cologuard. Stock down on mixed earnings & competition fears. Market undervalues future growth & overstates risks. Superior products & distribution moat. Early in large market penetration. Potential for double-digit revenue growth & expanding margins.
Read full article (1 min)